Altimmune (ALT) Net Income towards Common Stockholders (2010 - 2026)
Altimmune (ALT) posted quarterly Net Income towards Common Stockholders of -$22.6 million for Q1 2026, down 15.26% year-over-year from -$26.6 million in Q1 2025, and down 129.74% quarter-over-quarter from $75.9 million in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$22.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 15.26% year-over-year to -$22.6 million; the TTM figure through Mar 2026 stood at $12.1 million (up 113.44% YoY), while the FY2025 annual figure was $15.1 million, up 120.13% from the prior year.
- Net Income towards Common Stockholders eased to -$22.6 million in Q1 2026 per ALT's latest filing, from $75.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $75.9 million in Q4 2025 and bottomed at -$31.6 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged -$15.6 million across 5 years, with a median of -$20.7 million in 2023.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 228.09% — and 2025, when it jumped 427.24%.
- Altimmune's Net Income towards Common Stockholders stood at -$9.6 million in 2022, then sank by 228.09% to -$31.6 million in 2023, then climbed by 26.74% to -$23.2 million in 2024, then surged by 427.24% to $75.9 million in 2025, then tumbled by 129.74% to -$22.6 million in 2026.
- Business Quant data shows ALT's Net Income towards Common Stockholders at -$22.6 million in Q1 2026, $75.9 million in Q4 2025, and -$19.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Altimmune | 626.80 Mn | 626.80 Mn | - | -22.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.83 Mn |
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | -9.39 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -31.64 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.17 Mn |
| Mar 31, 2023 | -20.09 Mn |
| Dec 31, 2022 | -21.66 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.54 Mn |
| Dec 31, 2021 | -23.89 Mn |
| Sep 30, 2021 | -33.51 Mn |